kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Fc gamma RIIIA / CD16a (V176), Avi Tag (Avitag™), 25µg  

Recombinant Biotinylated Human Fc gamma RIIIA / CD16a (V176), Avi Tag (Avitag™), 25µg

Biotinylated Human Fc gamma RIIIA / CD16a (V176) Protein, Avitag™,His Tag (SPR & BLI verified)

recombinant, human, protein, biotinylated FCGR3A,CD16A,FCG3,FCGR3,IGFR3

More details


Availability: within 7 days

420,00 €

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Biotinylated Human CD16a (V176), Avitag,His Tag (SPR & BLI verified) (CDA-H82E9) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
Predicted N-terminus: Gly 17

Molecular Characterization
This protein carries an Avi tag (Avitag™)at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 25.5 kDa. The protein migrates as 40-55 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Less than 1.0 EU per μg by the LAL method.

>90% as determined by SDS-PAGE.

Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitute at 250 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8° C for 12 months in lyophilized state; -70° C for 3 months under sterile conditions after reconstitution.

Biotinylated Human FCGR3A / CD16a (V176) (Cat. No. CDA-H82E9) ELISA bioactivity
(1) Immobilized Yervoy Ipilimumab at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD16a, His Tag (Cat. No. CDA-H82E9) with a linear range of 0.016-0.5 μg/mL (QC tested).
(2) The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Biotinylated Human FCGR3A / CD16a (V176) Protein (Cat. No. CDA-H82E9) can bind Ipilimumab with affinity constant of around 158 nM (Routinely tested).

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s AviTagTM proteins confers to the purchaser the limited right to use the AviTagTM technology for non-commercial, or research use, or for purposes of evaluating the AviTagTM technology.
Commercial use of the AviTagTM technology to manufacture a commercial product, or use of the AviTagTM technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. 

Product specific literature

(1) Webster NL., et al., 2006, J Leukoc Biol. 79: 294-302.
(2) Nagarajan S., et al., 1995, J Biol Chem. 270: 25762-70.
(3) Ravetch JV., 1989, J. Exp. Med. 170:481.